Security key
75383L102
Rapport Therapeutics, Inc. - Common Stock, $0.001 par value per share (RAPP)
CUSIP: 75383L102
Q2 2024 13F Holders as of 30 Jun 2024
- Type / Class
- Equity / Common Stock, $0.001 par value per share
- Shares outstanding
- 47,779,015
- Total 13F shares
- 25,558,517
- Share change
- +25,558,517
- Total reported value
- $593,435,106
- Price per share
- $23.26
- Number of holders
- 35
- Value change
- +$593,435,106
- Number of buys
- 35
Report period
Q2 2024
Institutions
35
Top holders
10
RAPP full security history
Newer quarter: Q3 2024
Rapport Therapeutics, Inc. SEC filings
Rapport Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 75383L102
Recent filing periods:
Top shareholders of RAPP - Rapport Therapeutics, Inc. - Common Stock, $0.001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| ARCH Venture Partners XII, LLC |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
3,728,738
|
$37,212,805 | — | 10 Jun 2024 | |
| Bradley S. Galer |
3/4/5
|
Chief Medical Officer |
—
mixed-class rows
|
321,244
mixed-class rows
|
$1,970,311 | — | 06 Jun 2024 |
Institutional Holders of Rapport Therapeutics, Inc. - Common Stock, $0.001 par value per share (RAPP) as of Q2 2024
As of 30 Jun 2024,
Rapport Therapeutics, Inc. - Common Stock, $0.001 par value per share (RAPP) was held by
35 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
25,558,517 shares.
The largest 10 holders included
FMR LLC, ARCH Venture Management, LLC, Cormorant Asset Management, LP, Capital International Investors, JOHNSON & JOHNSON, Sofinnova Investments, Inc., T. Rowe Price Investment Management, Inc., PRICE T ROWE ASSOCIATES INC /MD/, ALLIANCEBERNSTEIN L.P., and PERCEPTIVE ADVISORS LLC.
This page lists
35
institutional shareholders reporting positions in this security
for the Q2 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2024 vs Q4 2025 Across Filers
Q4 2025 holders
144
Q2 2024 holders
35
Holder diff
-109
| Investor | Q4 2025 Shares | Q2 2024 Shares | Share Diff | Share Chg % | Q4 2025 Value $ | Q2 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.